A Two-eRNA-Based Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung Adenocarcinoma

<div>Independent prognosis analyses of risk scoring and clinic parameters: (a) univariable Cox regressive analyses; (b) the multivariable Cox regressive analyses.</div>

Journal of Immunology Research

fig11

Figure 11

Figure 11: A Two-eRNA-Based Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung Adenocarcinoma 